Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on April 23, 2026 by admin

Steady-state Bioequivalence Study of Aripiprazole for Injection in Patients With Schizophrenia.

Conditions: Schizophrenia

Interventions: Drug: Aripiprazole for Injection; Drug: Aripiprazole for Injection

Sponsors: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Not yet recruiting
CategoriesClinicalTrials.gov TagsAcademic research, Biopharma, News Approved, Schizophrenia spectrum

Post navigation

Previous PostPrevious The Download: introducing the 10 Things That Matter in AI Right Now
Next PostNext Playback Theatre Program for Adolescents and Youth
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.